Cannabinoid Encyclopedia

Focused research review

What do we know about CBG safety?

Human safety data on CBG are limited and often come from CBG-predominant or mixed CBD/CBG products, not a standardized pure-CBG medicine.

Updated July 2026 22 research sources Human and early research

The short answer

What is the bottom line?

CBG safety in people is not established by the current evidence. 1 2 3

The available human sources are small, product-specific, or survey-based. They can describe what was reported in those settings, but they do not define a general safety profile for every CBG product, dose, route, or combination with medicines. 1 2 3

What this means: Reported tolerability in one mixed or CBG-predominant product cannot be applied automatically to isolated CBG. Product composition, dose, route, other medicines, and the person using it all change the safety question. 1 2 3

How to read this answer: Reported tolerability in one mixed or CBG-predominant product cannot be applied automatically to isolated CBG. Product composition, dose, route, other medicines, and the person using it all change the safety question. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBG safety.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Human CBG safety evidence is limited and does not establish a universal safety profile. 1

  2. 2

    Mixed CBD/CBG products and CBG-predominant cannabis preparations answer different questions from isolated CBG. 2

  3. 3

    Potential interactions, dose, route, and formulation deserve the same scrutiny as the reported symptoms or tolerability findings. 3

Choose your question

What safety question are you asking?

Safety is not one result. Start with the product, dose, route, other medicines, and population represented in the source.

  1. 01Reader question

    What human safety studies exist?

    See the limited studies and surveys represented in the current CBG source set.

    Explore the evidence
  2. 02Reader question

    Does a mixed CBG product answer the isolated-CBG question?

    No. Product composition changes what a study can show.

    Explore the evidence
  3. 03Reader question

    What should I check in a safety source?

    Look for dose, route, formulation, adverse events, withdrawals, and other medicines.

    Explore the evidence

Research areas

What researchers studied about CBG safety

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...

This part of the literature focuses on Safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 3

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

5 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

9 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 22 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBG safety is not one kind of study. This source set includes 7 cell or laboratory studies, 6 animal studies, 5 narrative or expert reviews, and 3 clinical studies in people. 3

The recorded populations or models include animal models (6 sources), people or patients (5 sources), and cells or tissue models (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns (22 sources). Closely related outcome names can still describe different measurements. 5

The CBG safety source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 1

Study type
clinical study in people
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
human research

cell or laboratory study

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 2

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
mechanism-focused research

narrative or expert review

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
evidence still limited

animal study

Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner.

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 4

Study type
animal study
Population or model
animal models
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
preclinical research

clinical study in people

Safety study of cannabidiol products in healthy dogs.

On this page, this source examines CBG and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 5

Study type
clinical study in people
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on CBG safety should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Is CBG safe?

The current human evidence is too limited and product-specific to establish general CBG safety. The source details matter. 7

Are CBD and CBG combination studies the same as pure CBG studies?

No. A combination product includes more than one cannabinoid and may use a different dose, formulation, and route from isolated CBG. 8

What about CBG and medications?

The current CBG safety set does not establish a complete interaction profile. Medication questions need product-specific and clinical context. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). clinical study in people; human research PubMed 37947792 DOI 10.1080/15502783.2023.2280113
  2. 2
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research PubMed 39596290 DOI 10.3390/ijms252212224
  3. 3
    Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited PubMed 39598860 DOI 10.3390/molecules29225471
  4. 4
    Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. animal study; preclinical research PubMed 40523564 DOI 10.1016/j.pbb.2025.174053
  5. 5
    Safety study of cannabidiol products in healthy dogs. clinical study in people; human research PubMed 38496308 DOI 10.3389/fvets.2024.1349590
  6. 6
    Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. clinical study in people; mechanism-focused research PubMed 35246858 DOI 10.1111/jvp.13048
  7. 7
    Cannabinoids in clinical practice. narrative or expert review; evidence still limited PubMed 11152013 DOI 10.2165/00003495-200060060-00005
  8. 8
    Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. narrative or expert review; evidence still limited PubMed 40206058 DOI 10.3389/fphar.2025.1561385
  9. 9
    Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. narrative or expert review; evidence still limited PubMed 32628766 DOI 10.1093/clinchem/hvaa113
  10. 10
    Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? narrative or expert review; evidence still limited PubMed 37414155 DOI 10.1016/j.arr.2023.101998
  11. 11
    Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. animal study; evidence still limited PubMed 40326034 DOI 10.2174/0115701638363093250324035540
  12. 12
    Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. animal study; evidence still limited PubMed 39699828 DOI 10.1007/s12640-024-00724-0
See all 22 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 39598860
  2. Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39596290
  3. Cannabinoids in clinical practice. narrative or expert review; evidence still limited / 1 linked research note PubMed 11152013
  4. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). clinical study in people; human research / 1 linked research note PubMed 37947792
  5. Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. narrative or expert review; evidence still limited / 1 linked research note PubMed 40206058
  6. Safety study of cannabidiol products in healthy dogs. clinical study in people; human research / 1 linked research note PubMed 38496308
  7. Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. animal study; mechanism-focused research / 1 linked research note PubMed 36796712
  8. Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. animal study; mechanism-focused research / 1 linked research note PubMed 40540228
  9. Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. animal study; evidence still limited / 1 linked research note PubMed 39699828
  10. Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. animal study; preclinical research / 1 linked research note PubMed 40523564
  11. Non-psychotropic cannabinoids as inhibitors of TET1 protein. evidence still limited / 1 linked research note PubMed 35462234
  12. Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. animal study; evidence still limited / 1 linked research note PubMed 40326034
  13. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. cell or laboratory study; evidence still limited / 1 linked research note PubMed 33562819
  14. Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41548647
  15. Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? narrative or expert review; evidence still limited / 1 linked research note PubMed 37414155
  16. The impact of cannabigerol exposure on human endometrial stromal cells decidualization. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 42107483
  17. The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. cell or laboratory study; evidence still limited / 1 linked research note PubMed 36497400
  18. Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. cell or laboratory study; evidence still limited / 1 linked research note PubMed 42352060
  19. Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. narrative or expert review; evidence still limited / 1 linked research note PubMed 32628766
  20. Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36272108
  21. Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. animal study; mechanism-focused research / 1 linked research note PubMed 41934896
  22. Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. clinical study in people; mechanism-focused research / 1 linked research note PubMed 35246858